Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated data from their [212Pb]VMT-α-NET program will be presented at the ESMO Congress 2025 in Berlin, Germany. The presentation, scheduled for October 20, 2025, will be delivered by Dr. Thorvardur Halfdanarson from Mayo Clinic Comprehensive Cancer Center.
The presentation will focus on safety and preliminary efficacy data from 44 patients in dose-finding cohorts 1 and 2. The study involves patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who haven't received prior RPT. Previous interim results were presented at ASCO 2025, and additional follow-up data from 33 patients enrolled after Cohort 2's reopening will be available.
Perspective Therapeutics (NYSE AMERICAN: CATX) ha annunciato che dati aggiornati del loro programma [212Pb]VMT-α-NET saranno presentati al Congresso ESMO 2025 a Berlino, Germania. La presentazione, prevista per il 20 ottobre 2025, sarà tenuta dal Dr. Thorvardur Halfdanarson del Mayo Clinic Comprehensive Cancer Center.
La presentazione si concentrerà sui dati di sicurezza e sull'efficacia preliminare di 44 pazienti nei gruppi di dosaggio 1 e 2. Lo studio coinvolge pazienti con tumori neuroendocrini SSTR2-positivi, non resecabili o metastatici, che non hanno ricevuto precedenti trattamenti RPT. I risultati intermedi precedenti sono stati presentati all'ASCO 2025 e saranno disponibili dati di follow-up aggiuntivi di 33 pazienti arruolati dopo la riapertura del Gruppo 2.
Perspective Therapeutics (NYSE AMERICAN: CATX) anunció que se presentarán datos actualizados de su programa [212Pb]VMT-α-NET en el Congreso ESMO 2025 en Berlín, Alemania. La presentación, programada para el 20 de octubre de 2025, será realizada por el Dr. Thorvardur Halfdanarson del Mayo Clinic Comprehensive Cancer Center.
La presentación se centrará en datos de seguridad y eficacia preliminar de 44 pacientes en las cohortes de búsqueda de dosis 1 y 2. El estudio incluye pacientes con tumores neuroendocrinos SSTR2-positivos, irresecables o metastásicos, que no han recibido tratamiento previo con RPT. Los resultados intermedios previos se presentaron en ASCO 2025 y estarán disponibles datos adicionales de seguimiento de 33 pacientes inscritos tras la reapertura de la cohorte 2.
Perspective Therapeutics (NYSE AMERICAN: CATX)는 [212Pb]VMT-α-NET 프로그램의 최신 데이터를 독일 베를린에서 열리는 ESMO Congress 2025에서 발표할 예정입니다. 발표는 2025년 10월 20일에 Mayo Clinic Comprehensive Cancer Center의 Dr. Thorvardur Halfdanarson이 진행합니다.
발표는 용량 탐색 코호트 1 및 2에 참여한 44명의 환자의 안전성과 초기 효능 데이터에 중점을 둡니다. 연구 대상은 절제가 불가능하거나 전이된 SSTR2 양성 신경내분비종양 환자로, 이전에 RPT 치료를 받지 않은 환자들입니다. 이전 중간 결과는 ASCO 2025에서 발표되었으며, 코호트 2 재개 후 등록된 33명의 환자에 대한 추가 추적 데이터도 제공될 예정입니다.
Perspective Therapeutics (NYSE AMERICAN : CATX) a annoncé que des données mises à jour de leur programme [212Pb]VMT-α-NET seront présentées au Congrès ESMO 2025 à Berlin, en Allemagne. La présentation, prévue pour le 20 octobre 2025, sera réalisée par le Dr Thorvardur Halfdanarson du Mayo Clinic Comprehensive Cancer Center.
La présentation portera sur les données de sécurité et d'efficacité préliminaire de 44 patients dans les cohortes de recherche de dose 1 et 2. L'étude concerne des patients atteints de tumeurs neuroendocrines SSTR2-positives, non résécables ou métastatiques, n'ayant pas reçu de traitement RPT antérieur. Les résultats intermédiaires précédents ont été présentés à l'ASCO 2025, et des données de suivi supplémentaires provenant de 33 patients recrutés après la réouverture de la cohorte 2 seront disponibles.
Perspective Therapeutics (NYSE AMERICAN: CATX) gab bekannt, dass aktualisierte Daten ihres [212Pb]VMT-α-NET-Programms auf dem ESMO Kongress 2025 in Berlin, Deutschland, präsentiert werden. Die Präsentation, geplant für den 20. Oktober 2025, wird von Dr. Thorvardur Halfdanarson vom Mayo Clinic Comprehensive Cancer Center gehalten.
Der Fokus der Präsentation liegt auf Sicherheits- und vorläufigen Wirksamkeitsdaten von 44 Patienten in den Dosisfindungs-Kohorten 1 und 2. Die Studie umfasst Patienten mit nicht resezierbaren oder metastasierten SSTR2-positiven neuroendokrinen Tumoren, die zuvor keine RPT erhalten haben. Frühere Zwischenergebnisse wurden auf der ASCO 2025 vorgestellt, und zusätzliche Nachverfolgungsdaten von 33 Patienten, die nach der Wiedereröffnung der Kohorte 2 eingeschlossen wurden, werden verfügbar sein.
- None.
- None.
Insights
Perspective's NET therapy data acceptance at ESMO indicates promising clinical progress and potential for important efficacy results from dose-finding cohorts.
Perspective Therapeutics' [ 212 Pb]VMT-α-NET data acceptance for a mini oral presentation at ESMO 2025 is a positive development in their radiopharmaceutical program. The presentation will feature mature safety and preliminary efficacy data from 44 patients across two dose-finding cohorts with somatostatin receptor 2 positive (SSTR2+) neuroendocrine tumors.
This targeted alpha-particle therapy aims to deliver lead-212 specifically to SSTR2-expressing tumor sites, a mechanism potentially offering precision treatment for these challenging cancers. The mini oral format indicates the abstract reviewers found the data substantive enough to warrant dedicated presentation time rather than just a poster.
The presenter, Dr. Thorvardur Halfdanarson from Mayo Clinic, brings significant credibility to the presentation. The timing aligns with their clinical development timeline, as some of the 33 additional patients enrolled after Cohort 2 reopened will have completed at least 32 weeks of follow-up – sufficient for post-treatment scans if they received all four protocol-specified doses.
Perspective previously presented interim results at ASCO 2025 in May, suggesting this ESMO presentation will likely feature more mature data. While specific efficacy outcomes aren't revealed in this release, the acceptance for presentation indicates the company continues to generate clinical evidence that merits scientific scrutiny at major oncology conferences, a necessary step in advancing radiopharmaceutical candidates toward potential regulatory approval.
SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2025 taking place October 17 to 21, 2025 in Berlin, Germany. ESMO plans to release further details for regular abstracts on October 13, 2025.
| Presenter | Abstract Title | Presentation Details |
| Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center | [212Pb]VMT-α-NET targeted alpha-particle therapy (TAT) for advanced somatostatin receptor 2 positive (SSTR2+) neuroendocrine tumours (NETs): mature safety and preliminary efficacy for enrollment from dose-finding cohorts 1 and 2 (n=44) | Abstract Number: 1033MO Session Type: Mini Oral presentation Session Title: Mini oral session: NETs and endocrine tumours Session Date: October 20, 2025 Session Time: 8:30 – 10:00 am CEST Presentation Time: 9:00 am CEST |
About [212Pb]VMT-α-NET
Perspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company’s plans and the expected timing for the release of additional data from its clinical programs; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
When will Perspective Therapeutics (CATX) present their VMT-α-NET data at ESMO 2025?
What is the purpose of Perspective Therapeutics' VMT-α-NET clinical trial?
How many patients are included in the CATX VMT-α-NET data presentation at ESMO 2025?
What is the current status of Perspective Therapeutics' VMT-α-NET clinical trial?
Where can investors find the ESMO 2025 abstract for Perspective Therapeutics' presentation?
